When most people think of research and development (“R&D”), industries like technology, pharmaceuticals, or manufacturing typically come to mind. However, many apparel companies are performing activities that qualify for the R&D Tax Credit every day, often without realizing it.
As the apparel industry continues to evolve, companies are moving beyond aesthetics and focusing on performance, functionality and innovation, all of which can create meaningful opportunities to benefit from the R&D Tax Credit.
The federal R&D Tax Credit, codified under Internal Revenue Code Section 41, is designed to reward U.S. companies that invest in the development of new or improved products, processes, techniques, formulas, inventions or software. For eligible businesses, the credit can be used to offset income tax liability dollar-for-dollar, and for many start-up companies, payroll taxes as well.
Businesses with less than $5 million in gross receipts in the current taxable year and no gross receipts prior to the fifth preceding taxable year may qualify as a Qualified Small Business (“QSB”). QSBs can apply up to $500,000 of the R&D Tax Credit annually against payroll tax liability (i.e., FICA and Medicare), creating an immediate cash‑flow benefit even if the company is not yet profitable.
While apparel is often associated with style and branding, many companies are engaged in technical development and experimentation that may qualify for the R&D Tax Credit.
Apparel companies are frequently developing new materials to improve comfort and performance. These efforts may include:
Developing and/or enhancing fabric performance involves material science and testing, which can qualify for the R&D Tax Credit.
Beyond aesthetics, apparel companies often engineer garments to improve how they function in real-world conditions.
Examples include:
Creating prototypes and testing alternative designs to improve performance is a recognized qualifying activity for the R&D Tax Credit in the apparel industry.
Many apparel companies also invest in improving how their products are made.
This may include:
Process improvements and manufacturing innovation are common qualifying activities for the R&D Tax Credit.
In addition to physical products, apparel businesses often develop technologies to support operations, such as:
When these systems are designed in-house and involve technical challenges and iterative development, they may also qualify for the R&D Tax Credit.
It is important to distinguish between technical innovation and routine business activity.
Generally, the following activities do not qualify for the R&D Tax Credit in the apparel industry:
The key differentiator is whether the work involves technical uncertainty and a process of experimentation, not simply design preference.
Many apparel companies are already investing heavily in innovation to remain competitive. The R&D Tax Credit provides an opportunity to:
Despite this, the credit remains significantly underutilized in the apparel industry due to the misconception that it only applies to traditional “lab-based” research.
Today’s apparel companies are increasingly driven by innovation in materials, engineering, and performance. As a result, many are performing qualifying R&D activities as part of their standard product development processes.
Understanding how these activities align with IRS requirements is critical to maximizing available incentives while maintaining audit-ready documentation. If your organization is investing in improving fabrics, enhancing product performance, or optimizing manufacturing processes, there may be an opportunity to benefit from the R&D Tax Credit.
For more information on this topic, please contact a member of our team.
When people think of research and development (R&D), they often picture tech startups or pharmaceutical labs; rarely does the conversation turn to oil and gas. Yet in hubs like Houston, the energy industry is one of the most innovation-driven sectors in the United States and a prime candidate for the federal R&D Tax Credit under…
The Orphan Drug Credit (ODC) is a powerful federal tax incentive designed to encourage the development of treatments for rare diseases, generally defined as conditions affecting fewer than 200,000 individuals in the United States. For biotechnology and pharmaceutical companies advancing therapies through clinical trials, the ODC can deliver a significantly enhanced tax benefit compared to…
The life sciences industry is characterized by high-value intellectual property (“IP”), extensive research and development (R&D), complex regulatory environments, and global supply chains. Life sciences companies are increasingly global from day one where R&D is performed in one country, clinical trials in others, IP held centrally, and manufacturing and commercialization is performed elsewhere. These unique attributes create opportunity, but it also creates tax risk if global structuring and transfer pricing are not…
